Wednesday, July 17, 2024 | Baltimore, MD

Emergent BioSolutions scores FDA advisory panel’s vote to sell opioid overdose drug Narcan without prescription

February 16, 2023

Emergent BioSolutions Inc. (NYSE: EBS) could soon see its opioid overdose drug made more widely available after a regulatory advisory panel endorsed its use as an emergency over-the-counter treatment. The Food and Drug Administration’s Nonprescription Drugs Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee voted in a joint meeting Wednesday to recommend that Narcan Nasal Spray, Emergent’s opioid overdose antidote currently available with a prescription, be made available without requiring a doctor’s order.

Article Source: Washington Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.